Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Work In Process (2023 - 2025)

Tarsus Pharmaceuticals has reported Work In Process over the past 3 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Work In Process at $1.4 million for Q4 2025, up 129.64% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (up 129.64% YoY), and the annual figure for FY2025 was $1.4 million, up 129.64%.
  • Work In Process for Q4 2025 was $1.4 million at Tarsus Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Over the last five years, Work In Process for TARS hit a ceiling of $1.6 million in Q3 2024 and a floor of $392000.0 in Q4 2023.
  • Median Work In Process over the past 3 years was $1.0 million (2025), compared with a mean of $1.0 million.
  • Peak annual rise in Work In Process hit 129.64% in 2025, while the deepest fall reached 37.12% in 2025.
  • Tarsus Pharmaceuticals' Work In Process stood at $392000.0 in 2023, then skyrocketed by 56.63% to $614000.0 in 2024, then surged by 129.64% to $1.4 million in 2025.
  • The last three reported values for Work In Process were $1.4 million (Q4 2025), $1.0 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.